期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
CLAT联合微移植治疗难治性急性髓系白血病疗效观察
1
作者 廖惠钰 邓程新 +12 位作者 李敏明 陆泽生 赖沛龙 凌伟 黄励思 陈晓梅 王玉连 徐珍珍 黄欣 罗成伟 吴穗晶 杜欣 翁建宇 《循证医学》 2020年第3期163-168,180,共7页
目的探讨克拉屈滨联合阿糖胞苷和拓扑替康(CLAT)方案联合供者粒细胞集落刺激因子动员的外周血单个核细胞(微移植,G-PBSC)治疗难治性急性髓系白血病(acute myeloid leukemia,AML)的有效性及安全性。方法广东省人民医院血液科2015年4月至2... 目的探讨克拉屈滨联合阿糖胞苷和拓扑替康(CLAT)方案联合供者粒细胞集落刺激因子动员的外周血单个核细胞(微移植,G-PBSC)治疗难治性急性髓系白血病(acute myeloid leukemia,AML)的有效性及安全性。方法广东省人民医院血液科2015年4月至2018年11月接受CLAT方案联合供者G-PBSC治疗难治性AML患者。CLAT方案:克拉屈滨5 mg/m^2/d,静脉滴注,d1~d5;阿糖胞苷1 mg/m^2/d,静脉滴注,d1~d5;拓扑替康1.25 mg/m^2/d,口服,d1~d5;粒细胞集落刺激因子300μg/d,d6至中性粒细胞计数>1.0×10^9/L。目标剂量为单个核细胞2.0×10^8/kg或CD3+细胞1.0×10^8/kg。结果9例患者中位年龄34岁(范围:20~44岁);男性7例,女性2例,5例为原发难治性AML患者,4例为继发难治性AML患者。第一疗程疗4例(44.4%)患者获得完全缓解,3例(33.3%)患者获得部分缓解,总反应率为77.8%,累计完全缓解率为55.6%。9例患者均于微移植治疗后出现Ⅳ度骨髓抑制,中性粒细胞计数<0.5×10^9/L持续中位时间为14(7~21)天,血小板计数<20×10^9/L持续中位时间为8(0~19)天。结论CLAT方案联合供者粒细胞集落刺激因子动员后的外周血造血干细胞治疗难治性AML反应率高,不良反应可控。 展开更多
关键词 克拉屈滨 微移植 难治 急性髓系白血病 疗效
下载PDF
Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma:experience at an institution in southern China 被引量:21
2
作者 SONG wu wu sui-jing +4 位作者 HE Yu-long CAI Shi-rong ZHANG Chang-hua ZHANG Xin-hua ZHAN Wen-hua 《Chinese Medical Journal》 SCIE CAS CSCD 2009年第13期1486-1491,共6页
Background Previous studies have shown conflicting results on the relation between clinicopathologic features and prognosis of patients with colorectal mucinous, signet-ring cell, or non-mucinous adenocarcinoma; only ... Background Previous studies have shown conflicting results on the relation between clinicopathologic features and prognosis of patients with colorectal mucinous, signet-ring cell, or non-mucinous adenocarcinoma; only few such studies have been performed in China. This retrospective study analyzed data from our department to investigate clinicopathologic characteristics, prognosis and possible correlations of three histologic types - colorectal mucinous, signet-ring cell, and non-mucinous adenocarcinoma, to clarify the bases for observed differences which may lead to development of targeted therapies Methods Of 2079 patients diagnosed with colorectal cancer between 1994 and 2007, 144 had mucinous, 25 had signet-ring cell, and 1837 had non-mucinous adenocarcinoma. Their clinicopathologic parameters and survival were analyzed using established statistical methodologies. Results Mucinous and signet-ring cell adenocarcinomas were common in younger patients (P 〈0.001). Location, size and disease stage differed significantly among the three types. Signet-ring cell tumors were more commonly found in the rectum than mucinous and non-mucinous adenocarcinoma (P 〈0.001). Mucinous and signet-ring cell tumors presented in a later stage in life more often than non-mucinous adenocarcinoma, with lymph node involvement, serosal infiltration, peritoneal dissemination, and adjacent organ invasion (P 〈0.01). The rate of radical resection, hepatic metastasis and local recurrence did not differ among types (P 〉0.05). Compared with patients with non-mucinous adenocarcinoma, patients with mucinous and signet-ring cell tumors who underwent potentially curative resections or stage Ⅱ/Ⅲ disease had poorer long-term overall survival. Survival did not differ by type for patients with either stage Ⅰ or Ⅳ disease (P 〉0.05). Conclusions Mucinous and signet-ring cell adenocarcinoma have unique carcinogenesis and similar biologic behavior. Our study confirms that both histologic types, especially signet-ring cell tumors, are independent, negative prognostic factors for patients with colorectal cancer. Type does not appear to have a significant effect on survival when disease is either stage Ⅰ or Ⅳ at presentation. 展开更多
关键词 colorectal carcinoma mucinous adenocarcinoma signet-ring cell carcinoma PROGNOSIS
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部